Shares of pharmaceutical major Biocon experienced a significant dip of 9% in early Monday trading following the release of its March quarter results, only to recover most of these losses as the session progressed. Despite the initial volatility, market analysts largely maintained a positive stance on the Bengaluru-based firm's prospects.
Biocon reported revenue for the quarter that aligned with Street expectations, while its Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) notably exceeded forecasts. However, overall earnings for the quarter were in line with estimates, primarily due to higher-than-expected interest costs and reduced other income.
Biosimilars Drive Growth Amidst Facility Upgrades
Robust revenue growth was primarily fueled by the company's biosimilars and generics segments. Conversely, the contract research, development, and manufacturing organization (CRDMO) arm, Syngene, reportedly weighed on the overall performance during the March quarter.
Nuvama analysts noted that Biocon's Q4FY26 growth moderated as the company actively upgraded its facilities. This strategic move aims to scale up capacity in anticipation of increased demand across key markets in the United States and Europe.
Key Triggers for Future Performance
- US Market: Nuvama highlighted several key triggers for the biosimilars business in the US, including sustained traction in Yesintek market share gains, the recent launch of the Denosumab biosimilar, and the highly anticipated launch of Aflibercept in the second half of FY2027.
- European Expansion: In Europe, Biocon expects continued momentum for Yesintek, supported by ongoing ramp-ups, recent approval in Switzerland, and the approval of its auto-injector in the UK. The company has also rolled out Denosumab in Germany, with Abevmy and Ogivri continuing their scale-up.
Considering the projected improvements in the biosimilar business and Biocon's sharpened focus on profitable growth, Nuvama conservatively anticipates a 200 basis point margin expansion over FY2026–28E, projecting a 21% Compound Annual Growth Rate (CAGR) for biosimilar revenue. Potential improvements in Syngene's performance could also serve as a significant positive trigger for Biocon's overall financial health.
Analyst Recommendations and Outlook
Brokerage firm MOFSL reiterated a 'Buy' recommendation on Biocon stock, asserting that the company is currently at an inflection point and poised for a better outlook from FY2027 onwards. MOFSL projects a 16% growth in biosimilar sales and an 18% increase in the generics segment. This growth is expected to be propelled by new product launches, the scale-up of existing offerings, and enhanced capacity to support in-house production.
Nuvama analysts also forecast Biocon's revenue and EBITDA to grow at 17% and 23%, respectively, with a higher Profit After Tax (PAT) growth driven by reduced interest costs stemming from debt repayment. Both firms noted that Biocon has largely moved past its significant capital expenditure phase for its biosimilar and generics segments, with a promising product pipeline both commercialized and under development, signaling continued market strengthening and expansion.